Xilio Therapeutics Inc. (NASDAQ: XLO)
$1.01
-0.0100 ( -0.98% ) 91.4K
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
Market Data
Open
$1.01
Previous close
$1.02
Volume
91.4K
Market cap
$37.28M
Day range
$0.99 - $1.05
52 week range
$0.49 - $2.94
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
3 | Insider transactions | 1 | Apr 03, 2024 |
4 | Insider transactions | 1 | Apr 03, 2024 |
10-k | Annual reports | 91 | Apr 01, 2024 |
8-k | 8K-related | 14 | Apr 01, 2024 |
8-k | 8K-related | 13 | Mar 28, 2024 |
8-k | 8K-related | 18 | Mar 28, 2024 |
4 | Insider transactions | 1 | Feb 09, 2024 |
8-k | 8K-related | 12 | Jan 19, 2024 |
4 | Insider transactions | 1 | Jan 16, 2024 |
4 | Insider transactions | 1 | Jan 03, 2024 |